Free Writing Prospectus Dated August 5, 2019.
Filed pursuant to Rule 433. Registration No. 333-233020.

An Innovative Platform in Oral and Nasal Antibody Administration A Novel Approach for Treatment of Hepatocellular Carcinoma T L S A : T I L S : INVESTOR PRESENTATION A u g u s t 2 0 1 9



DISCLAIMER AND FORWARD LOOKING STATEMENTS The content of this presentation has been prepared for the purpose of providing general information about, and an overview of, the Company and its business . It is not intended to be a complete review of all matters concerning the Company and nor has it been independently verified . Whilst the presentation has been prepared in good faith and the Company has taken all reasonable care to ensure the information and facts contained in this presentation are accurate and up - to - date, it does not make any representation or warranty, express or implied, as to the accuracy or completeness of any information included in this presentation . Neither the Company nor any of its directors, officers, employees or agents shall be liable for any loss arising directly or indirectly from the use of or reliance upon this presentation or in relation to the adequacy, accuracy, completeness or reasonableness of the information it contains . All and any such liability is expressly excluded to the fullest extent permitted by law . The information in this presentation is subject to updating, completion, revision, further verification and amendment without notice . This presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities including ordinary shares in the Company nor does it constitute an invitation or inducement to engage in investment activity in relation to any securities, including the ordinary shares of the Company . It does not purport to contain information that shall form the basis of or be relied upon in making such investment decisions . If you require any advice, please consult with a professional financial adviser . All investments are subject to risk . The value of securities may go down as well as up . Past performance cannot be relied on as a guide for future performance . This presentation may contain certain forward - looking statements concerning the financial condition, results of operations and businesses of the Company . All statements other than statements of historical fact are, or may be deemed to be, forward - looking statements . Forward - looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements . All forward - looking statements contained in this presentation are expressly qualified in their entirety by the cautionary statements contained or referred to in this section . You should not place undue reliance on forward - looking statements . Each forward - looking statement speaks only as of the date of this presentation . The Company does not undertake any obligation to publicly update or revise any forward - looking statement as a result of new information, future events or other information . In light of these risks, results could differ materially from those stated, implied or inferred from the forward - looking statements contained in this presentation . In the UK, this presentation has not been approved by an authorised person and is being distributed on the basis that each person in the UK to whom it is issued is reasonably believed to be such a person as is described in Article 19 (investment professionals) or Article 49 (high net worth companies, unincorporated associations etc . ) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005 / 1529 ) or are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 ) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated . Persons who do not fall within such descriptions may not act upon the information contained in this presentation . 2



FREE WRITING PROSPECTUS We have filed a registration statement (including a preliminary prospectus) with the SEC for the offering to which this presentation relates . The registration statement has not yet become effective . Before you invest, you should read the preliminary prospectus in the registration statement (including the risk factors described therein) and other documents we have filed with the SEC for more complete information about us and the offering . You may access these documents for free by visiting EDGAR on the SEC Web site at http : //www . sec . gov . The preliminary prospectus, dated August 5 , 2019 , is available on the SEC Web site at http : //www . sec . gov . Alternatively, we or any underwriter participating in the offering will arrange to send you the prospectus if you contact ThinkEquity, a division of Fordham Financial Management, Inc . , located at 17 State Street, 22 nd Floor, New York, New York 10004 , by telephone at ( 877 ) 436 - 3673 , or by email at prospectus@think - equity . com . 3



I SS U E R : T I ZI A NA L I FE SCI EN CE S, PL C Approximate Offering Size $10.0 Million of ADSs Listings/Symbols Nasdaq Global Market / TLSA and AIM / TLS Over - Allotment Option 1 5 % Use of Proceeds Advance the clinical development of Foralumab and Milciclib, and other research and development programs, working capital and other general corporate purposes Sole Book - Running Manager ThinkEquity, a division of Fordham Financial Management, Inc. OFFERING SUMMARY 4



Innovative platform technology for oral and nasal formulations can transform the administration of Monoclonal Antibodies (‘mAbs’) Two de - risked assets in clinical evaluation that target the root causes of autoimmune/inflammatory diseases and cancer Milciclib has received ‘Orphan Drug Designation’ in US and EU for treatment of thymic carcinoma/thymoma (TC/T) Assets for unmet needs in a multi billion - dollar addressable market □ NASH - $35 billion □ Crohn’s Disease - $10 billion/year by 2025 □ Liver cancer - $1.5 billion/year by 2022 Strong intellectual property □ 255 patents approved and 30 pending □ Covers composition of matter, process and disease indications □ Oral formulation technology applicable to other mAbs therapeutics Experienced and successful biotech management team A leverageable biotechnology platform for use in additional therapeutics INVESTMENT HIGHLIGHTS 5 Orphan Drug Designation Met primary and secondary endpoints in 2 separate Phase 2 trials in TC/T. Phase 2a in sorafenib - resistant patients completed Well - tolerated topline data reported July 2019 Nasal Trial: Phase 2 starting shortly. Phase 1 trial completed Data - August 2019 Oral Trial: In consultation with FDA for IND submission 5



□ Inventor of Oral Formulation of Foralumab □ Co - founder , EVP & CSO of Synergy Pharmaceuticals, NASDAQ: SGYP □ The pioneer of GC - C agonist technology inventor of TRULANCE approved for Chronic constipation and IBS - C □ VP, Callisto Pharmaceuticals LEADERSHIP AND EXECUTIVE TEAM Kunwar Shailubhai PhD, MBA CEO & CSO Dr . Shailubhai brings more than 25 years of experience within the life science industry, combined with a distinguished track record of success in translating drugs from concept through commercialization to market . He also currently serves as CEO of Rasna Therapeutics, Inc . , a developer of therapeutics to address the high unmet need that exists for AML and other forms of leukemia . Dr . Shailubhai has been serving as a member of board of Tiziana Life Sciences since 2015 . He actively played key roles in development of growth strategies through several key licensing of technologies and drug candidates . Dr . Shailubhai steered the Company through prioritization of projects to focus on novel drug candidates for treatment of autoimmune and inflammatory diseases and cancer . As co - founder, EVP and CSO of Synergy Pharmaceuticals, Inc . (NASDAQ : SGYP) he led the non - clinical, CMC and clinical development of Trulance™ from inception to approval by the FDA, having co - invented and pioneered Synergy’s platform technology for functional GI disorders, inflammatory bowel disease, GI cancer and other human diseases . Dr . Shailubhai as the chief architect of the IP estate, directed all aspects of IP management, including timely submission of patent applications, directing office actions and coordinating with IP attorneys . Earlier, from 2003 until 2008 , Dr . Shailubhai served as Senior Vice President, Drug Discovery and from 2001 to 2003 , he held the position of Vice President, Drug Discovery at Synergy, where he pioneered therapeutic applications of GC - C agonists in a variety of human diseases such as Asthma, COPD and cholesterol lowering . Prior to Synergy, he was with Monsanto Company, serving as Group Leader, Cancer Prevention and previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland . Dr . Shailubhai received his Ph . D . in microbiology from the University of Baroda, India, and his MBA from the University of Missouri, St . Louis . He has more than 36 issued patents, 20 patent applications and over 50 peer - reviewed publications . Tiziano Lazzaretti Chief Financial Officer Mr . Lazzaretti has extensive experience in the healthcare and pharmaceutical industry and joined Tiziana from Pharmentis Srl, a spin - off from Teva Ratiopharm, where he served as Group Finance Director from 2011 . Prior to this, Mr . Lazzaretti was Executive Director at Alliance Boots Healthcare, and held senior positions at Accenture, SNIA Spa and Fiat Group . Mr . Lazzaretti has a Bachelor of Science (BSc Hons) in Accounting and Finance from the University of Turin, Italy, was awarded a Master in Business Administration (MBA) from Bocconi University, Milan and studied Corporate Finance at the London Business School . 6



Gabriele Cerrone Executive Chairman □ Proven track record & experience in financing biotechnology companies □ Founder and chairman of two biotech companies with market cap over $2 B □ Inhibitex sale $2.5 B □ Synergy / Trovagene / Gensignia / Rasna / Contravir / Siga Technologies □ MBA, Stern School of Business, NY, USA BOARD OF DIRECTORS Leopoldo Zambeletti Non - Executive Director □ Former head of Life Sciences M&A for Credit Suisse, EU □ Investment Banking experience at JP Morgan and Credit Suisse □ Non - exec. director several biotech companies Willy Simon Non - Executive Director □ Career as an executive in the banking and corporate finance sector and director of publicly listed companies □ Kredietbank N.V., Citibank, Generale Bank NL, CEO of Fortis Investment Management □ Chairman of Bank Oyens & van Eeghen, Partner at Redi & Partners SCIENTIFIC ADVISORY Howard Weiner, MD □ Professor of Neurology at Harvard Med □ Director and Founder of the Partners MS Center and Co - Director of the Ann Romney Center for Neurologic Diseases □ Pioneered investigation of the mucosal immune system for the treatment of autoimmune and other diseases Kevin Herold, MD □ Professor of Immunobiology and Medicine and Deputy Director, Yale Center for Clinical Investigation □ Director of the Yale Diabetes Center and Director of the TrialNet Center at Yale □ Expert in autoimmune diseases and anti - CD3 monoclonal antibody therapies Arun Sanyal MD □ Charles Caravati Distinguished Professor and Chair, Division of Gastroenterology, Hepatology and Nutrition at Virginia Commonwealth University School of Medicine □ Leader in the field of liver diseases Napoleone Ferrara MD □ Inventor of Avastin® ($6.67Bn/yr)*; 2010 Lasker Award □ Senior Deputy Director Basic Sciences, Moores Cancer Center, UC San Diego □ Distinguished Prof of Pathology, School of Medicine, UC San Diego 7



platform enables… □ Costly Infusion Center □ Poor patient compliance □ Higher toxicity □ Systemic treatment to affect whole body □ Infusion related side effects TODAY’S ANTIBODY ADMINISTRATION OPTIONS ARE MOSTLY I.V. Antibodies (mAbs) reformulated for oral administration Antibodies (mAbs) reformulated for nasal administration Ease of use Superior compliance Topical action in gut Minimized toxicity Take home Rx No costly infusion PATIENT & PROVIDER BENEFITS THE LARGE MARKET OPPORTUNITY Market opportunity for mAb therapeutics is greater than $ 86 BILLION A REVOLUTIONARY PLATFORM SWITCH ANTIBODY ADMINSTRATION FROM INTRAVENOUS TO ORAL AND NASAL ROUTES 8 8 ROUTE OF ORAL OR NASAL ADMINISTRATION DEPENDS ON DISEASES



HEALTHY LIVER NON - ALCOHOLIC FATTY LIVER DISEASE NALFD 25 - 30% of Population C I RRH O S I S H E PATOCELLULAR CANCER amage Immune cells infiltration Foralumab (Anti - CD3) for NASH and Crohn’s Disease □ NASH global market ~ $35 B/year □ Crohn’s Disease market: $10B /year by 2025 □ Oral/nasal treatment is a novel, completely differentiated approach □ Strong IP on the ‘Revolutionary’ approach with significant market potential THE MULTI BILLION DOLLAR MARKET FOR LIVER DISEASES AND CROHN’S DISEASE EXCESSIVE FAT DEPOSITS LEAD TO LIVER INFLAMMATION INFLAMMATORY AND FIBROTIC PROCESSES LEAD TO MALIGNANCY NON - ALCOHOLIC STEATOHEPATITIS NASH Generally Asymptomatic Reversible 3 - 5% of Population Reversible Ƒ Milciclib for Liver Cancer □ HCC ($1.5B /year by 2022): Medical need to have a safer and effective drug with higher responder rates □ Milciclib: An oral drug with completely differentiated MOA with long - term safety □ Superior safety profile 20% Over 10 Years H B V / HCV X Irreversible Liver D 9



DISCOVERY L E A D OPTIMIZATION PRE - CLINICAL I N D PHASE 1 PHASE 2 PHASE 3 DEVELOPMENT PIPELINE Intranasal formulation for Neurodegenerative disease Nasal Administration Enteric coated capsules for NASH Oral Administration Enteric coated capsules for Crohn’s disease Oral Administration Crohn’s disease I.V. Administration – Conducted by Novimmune Thymic Carcinoma / Thymoma Orphan Drug Designation in U.S. and E.U Milciclib + Gemcitabine in refractory solid tumors Potential Adjuvant Treatment HCC monotherapy Sorafenib Resistant Patient HCC combination with a Tyrosine Kinase Inhibitor Potentially for synergism BE G I N N I N G PHASE 2 Nasal Trial PHASE 2a C O M P L E T ED I.V. Trial TWO PHASE 2 TRAILS COMPLETED TC / T Oral PHASE 2a C O M P L ETE D HCC Oral Monotherapy 1 0 1 0 From pipeline chart in F1



P L A T F O R M T E C H O L O G I E S NASAL ADMINISTRATION Phase 1 trial completed for related neurodegenerative diseases such as Progressive Multiple Sclerosis (Pro - MS): Top line data expected August 2019 ORAL ADMINISTRATION Phase 1 trial with enteric coated capsule formulation for oral administration (2H 2019) is expected to start shortly after meeting with FDA (Crohn’s Disease Division) A BIOTECHNOLOGY PLATFORM ENABLING ORAL AND NASAL ADMINISTRATION OF FORALUMAB AND OTHER MONOCLONAL ANTIBODIES 11



OKT3 M U R O M O N A B CHAGLYCD3 O T E L I X I Z U M A B NUVION V I S I L I Z U M A B HOKT3 1(ALA - ALA) TEPLIZUMAB NI - 0401 F O R A L U M A B I g G 2 a IgG1 * A g l y I g G 2 *AA I g G 2 *AA Chimeric & H u m an i z ed H u m an i z ed H u m an i z ed IgG1 *AE Fully Human Fully Mouse Approved by the FDA for solid organ transplantation immuno - suppression THE ONLY FULLY HUMAN ANTI - CD3 MAB CD3 - SPECIFIC MONOCLONAL ANTIBODIES IN CLINICAL DEVELOPMENT Oral and Nasal Administration Market Opportunities Tiziana’s platform of oral and nasal mAbs administration potentially enhances efficacy and reduces toxicity 12





a g Patent covers nd other mAbs ANTI - CD 3 ANTIBODY FORMULATIONS Applicant(s): Tiziana Life Sciences PLC Inventor(s): SHAILUBHAI, Kunwar US Non - Provisional Patent Application No.:62/380,652, filed August 29, 2016 PCT Application PCT/US2017/049211, filed, Aug 29, 2017 Patent estate □ In - licensed exclusive license for composition of matter □ Composition of matter patent for oral formulation □ Additional patent applications pendin □ Oral formulation technology applicable to other mAbs Nasal administration of □ Proof - of - concept demonstrated in animal studies □ Phase 1 study for neurodegenerative diseases at Brigham and Women’s Hospital, Harvard Medical School; completed dosing, well - tolerated up to 250 µg □ Top line data expected August 2019 □ In - licensed nasal delivery technology from Brigham and Women’s Hospital, Harvard Medical School ORAL AND NASAL FORMULATION PATENTS PENDING 14



□ Determined the immunologic effects and safety of orally delivered anti - CD 3 antibody in patients with moderate - to - severe ulcerative colitis (UC) □ Six subjects received oral OKT 3 * Boden, E. K., Canavan, J. B., Moran, C. J., McCann, K., Dunn, W. A., Farraye, F. A., Ananthakrishnan, A. N., Yajnik, V., Gandhi, R., Nguyen, D. D., Bhan, A. K., Weiner, H. L., Korzenik, J. R., Snapper, S. B. Immunologic alterations associated with oral delivery of anti - CD3 (OKT3) monoclonal antibodies in patients with moderate - to - severe ulcerative colitis. Crohn's & Colitis 360 (2019). 183: 240 - 246. KEY FINDINGS 1. The biologic response to treatment with oral anti - CD3 were increased proliferation and anti - inflammatory gene expression profile in peripheral blood mononuclear cells 2. 3 of 6 patients had a clinical response including one patient in clinical remission 3. Treatment was well - tolerated with no serious treatment - related adverse events FINDINGS SUPPORT TIZIANA’S ORAL PLATFORM THIRD PARTY RESEARCHERS IN PEER - REVIEWED, CROHN’S & COLITIS 360* 15



OKT3, a murine mAb, was withdrawn from the market due to severe side effect s Foralumab is a fully human anti - CD3 mAb with minimal side effects STUDY DESIGN S A FE T Y I MM U N O L O G I C A L EFFICACY BIOMARKERS □ 36 subjects with NASH and type II diabetes □ Randomized, single - blinded, placebo - controlled □ 9 per group, not powered for statistical significance □ 0.2, 1.0, 5.0 mg or placebo daily for 30 days □ Primary endpoints: safety and trends in immunomodulation □ Secondary endpoint: indication or trend of efficacy through biomarkers □ Follow up: Days 0, 14, 30, 60 □ Hadassah Medical Center, Jerusalem Israel □ Well tolerated by all patients in all groups □ No systemic drug - related adverse events □ No changes in vital signs, serum biochemistry and hematological parameters during treatment or follow - up periods (30 - days post - treatment) □ No changes in lymphocyte and CD+ cell counts □ No changes in weight or BMI or HbA1C lipid GLP - 1, or CRP levels in any of the groups □ Increases in Treg markers consistent with induction of Tregs □ Anti - inflammatory markers ↑ □ CD4+CD25+LAP+ Treg cells ,TGFβ ↑ □ Positive trends, some of which were statistically significant □ AST ↓ – liver enzyme indicating reduced liver inflammation □ Glucose ↓ – favorable for subjects with type - 2 diabetes □ Insulin ↓ – favorable for subjects with type - 2 diabetes PROOF - OF - CONCEPT IN NASH PATIENTS ORAL TREATMENT WITH MURINE ANTI - CD 3 (OKT 3 ) EFFECTIVE IN A PHASE 2 TRIAL WITH NASH 1 16 Sources: 1) Lalazar, G., Mizrahi, M., Turgeman, I., Adar, T., Ya’Acov, A. B., Shabat, Y., . . . Ilan, Y. (2015). Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T - cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo - Controlled Trial. Journal of Clinical Immunology, 35(4), 399 - 407.



KEY FINDINGS 1. Foralumab is as potent as OKT3 2. Treatment is effective in humanized mice studies 3. Mechanism of action is via activation of Tregs that systemically circulate to elicit targeted immunomodulation FORALUMAB IS FUNCTIONALLY EQUIVALENT TO OKT3 Oral Treatment prevents skin xenograft rejection in mice with human immune systems Mineko Ogura, Songyan Deng, Paula Preston - Hurlburt, Hideki Ogura, Kunwar Shailubhai, Chantal Kuhn, Howard L Weiner, and Kevan C. Herold Clinical Immunol, 2017. 183: 240 - 246 17



KEY FINDINGS 1. Teplizumab (humanized OKT3), administered intravenously, significantly slowed progression to clinical Type 1 diabetes, with a median delay in the diagnosis of diabetes of 2 years 2. At the end of the trial, 57% of subjects treated with Teplizumab showed slowed progression to development of Type 1 diabetes, while 72% of the placebo - treated subjects progressed to clinical diabetes POTENTIAL TO TREAT TYPE I DIABETES New England Journal of Medicine* provides clinical evidence for the potential use of a humanized anti - CD3 mAb for treatment of type 1 diabetes *K. Herold, B. Bundy, S.A. Long, J. Bluestone, L. Dimeglio, M. Dufort, S. Gitelman, P. Gottlieb, J. Krischer, P. Linsley, J. Marks, W. Moore, A. Moran, H. Rodriguez, W. Russell, D. Schatz, J. Skyler, E. Tsalikian, D. Wherrett, A - G. Ziegler and C. Greenbaum. “ An Anti - CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes,”. epub. June 9 2019 18



PROGRESS AND RECENT EVENTS 1 July 2019 Independent Third - Party Article in NewEngland JournalofMedicine reports on Intravenous Treatment with a Humanized Anti - CD3 mAb showing delays in progression of Type 1 Diabetes A recently published study in The New England Journal of Medicine titled,“An Anti - CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes,” demonstrates potential use of an anti - CD3 mAb in the prevention or treatment of Type 1 diabetes.Teplizumab is being developed by Provention Bio. The published study was funded by the National Institute of Health and others and was conducted by investigators at numerous institutions in the field of immunology and pediatrics including Yale University and Vanderbilt University. 19 Ƒ Beginning Phase 2 trial Ƒ Advancing the clinical development of orally - administered Foralumab for the treatment of NASH and Crohn’s disease Ƒ Proof - of - concept for oral administration with mAbs was provided by three independent third - party publications



PROGRESS AND RECENT EVENTS 22 July 2019 Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in Sorafenib - refractory or - intolerant patients with unresectable or metastatic Hepatocellular Carcinoma 20 □ Milciclib was well tolerated and no drug related deaths were reported □ 28 out of 31 treated patients were evaluable,with 14 patients completing the 6 - month study duration □ 9 patients continued treatment under compassionate use, of which 5 are currently continuing with treatment Ƒ Beginning Phase 2b Ƒ Progressing the clinical development and obtaining regulatory approval for Milciclib, as a monotherapy in HCC and as a combination therapy for the treatment of refractory solid tumors (cancers which are non - responsive or become resistant to treatment) Ƒ Efficacy and exploratory endpoint results from Phase 2a monotherapy trial available in September 2019



A PAN - CDK INHIBITOR FOR TREATMENT OF HEPATOCELLULAR CARCINOMA AND SOLID TUMORS Source: Petrick J. Clin. Onc 34 (15) (2016) pg 1787 - 1795 Incidence of HCC is steadily increasing in males and females and subpopulations in US 21



SMALL MOLECULE PAN - CDK INHIBITOR □ Orally - bioavailable small molecule with potent anti - tumor activity in a wide range of animal models □ Inhibitor of kinases associated with cancer cell growth including CDK1, CDK2, CDK4 CDK5, CDK7 and src - family kinases □ Inhibits signaling pathways for hepato - carcinogenesis ▪ Well tolerated in 316 patients Ƒ Improved toxicity profile over the current standard of care anticipated A drug with completely differentiated MOA and long - term safety 22



Trial design: Oral administration (100 mg/day). Total patients 30 to be enrolled. Duration 6 months Primary end point: safety Secondary end points: PFS, ORR & TTP Exploratory: AFP and miRNA profiling Compassionate use: Upon request of patients with EC approval Trial complete: Data from 28 out of 31 evaluable sorafenib - resistant HCC patients □ 14 patients completed treatment as per protocol □ Nine approved for compassionate use. Four patients completed 9, 11, 13 and 16 months, respectively. Five patients continuing with the treatment at 8,9,9,9 and 11 months, respectively □ No drug related deaths in the trial □ Treatment was well - tolerated □ Adverse events were manageable □ MRI imaging and micro RNA profiling data available in September 2019 23 CLINICAL DATA FROM MILCICLIB PHASE 2A TRIAL IN SORAFENIB - RESISTANT HCC PATIENTS



THYMIC CARCINOMA AND THYMOMA UPDATES □ Two Phase 2 trials with Milciclib in US, Italy and France o Trial 006: Thymic carcinoma and Thymoma mixed population (72 patients) o Trial 007: Thymic carcinoma and Thymoma mixed population (30 patients ) □ Rare cancers with very few cases: Orphan Disease Indications □ Positive clinical data □ Primary endpoint (progression free survival) and secondary endpoint (overall survival) met in both trials separately □ Thymic carcinoma is an aggressive metastatic cancer and it has no approved therapy □ Milciclib as a single agent met primary as well as secondary endpoints in thymic carcinoma in both trials □ Under compassionate use, few patients continued the treatment for over five years □ Seeking guidance from FDA/EMA regarding conditional marketing approval 24



MILCICLIB OVERCOMES DRUG RESISTANCE KEY FINDINGS 1. Milciclib well - tolerated with manageable side effects with refractory solid tumors 2. Oral treatment in combination with gemcitabine demonstrated clinical activity in patients who were non - responder to existing chemotherapeutic drugs 3. Recommended Phase 2 dose (RPD) found to be 150 mg/day (7 day off/7day on cycle) 4. Overall response rate was 36% 5. Results suggest further evaluation in other solid cancers either as monotherapy or combo - therapy PATIENTS RAPIDLY ACQUIRE RESISTANCE TOWARDS CHEMOTHERAPIES Phase 1 Dose - Escalation Study of Milciclib in Combination with Gemcitabine in Patients with Refractory Solid Tumors* Swimmerplot showing treatment duration. Tumor type was indicated for patients having a prolonged stable disease or a partial response. M Milciclib; G gemcitabine. * Cancer Chemotherapy and Pharmacology, June 2017, 79(6), 1257 - 1265 25



TZ L S - 5 0 1 Fully human anti - interleukin - 6 receptor (IL - 6R) monoclonal antibody (mAb) to treat inflammatory disease GROWTH OPPORTUNUITY PRECLINICAL PIPELINE A FULLY HUMAN ANTI IL - 6 RECEPTOR MAB MECHANISM INDICATIONS OPPORTUNITY COMPETITIVE EDGE IP/OWNERSHIP □ Interleukin - 6 (IL - 6) is a potent cytokine regulating cell growth, differentiation and immune responses. □ Excessive production of IL - 6 and its receptor IL - 6R are key drivers of chronic inflammation and inflammatory disease □ Multiple Myeloma □ Could be used in combination with Foralumab for NASH and other autoimmune and inflammatory diseases such rheumatoid arthritis □ Anticipated to exert synergistic effect with Foralumab for inflammatory diseases □ >$35 billion market Ƒ Differs from other anti - IL - 6R mAb's (e.g. tocilizumab), by acting not only on membrane - bound IL - 6R, but also on soluble IL - 6R, and is also able to deplete circulating levels of IL - 6 in blood □ Exclusive license from Novimmune (NI - 1201) □ Method of use in combination with anti - CD3 patent pending 26



INTELLECTUAL PROPERTY PORTFOLIO T Z L S - 4 0 1 T T Z L S - 2 0 1 FAMILY SUBJECT PRIORITY STATUS EXPIRES JURISDICTION Methods of Use (Autoimmune or Inflammatory diseases and disorders) 2004 Issued 2025 Australia, Canada, China, Hong Kong, Israel, Japan, Mexico, Norway, Singapore, South Africa, Ukraine, Armenia, Austria, Azerbaijan, Belgium, Belarus, Switzerland, Germany, Denmark, Spain, France, United Kingdom, Ireland, Italy, Kyrgyzstan, Kazakhstan, Luxembourg, Moldova, Netherlands, Portugal, Russian Federation, Sweden, Tajikistan, Turkmenistan, Composition and methods of use 2004 Issued/ P e n d i ng 2025 US, Armenia, Australia, Austria, Azerbaijan, Belarus, Canada, China, Denmark, France, Germany, Hong Kong, India, Israel, Italy, Japan, Kazakhstan, Kyrgyzstan, Mexico, Moldova, Netherlands, Norway, Republic of Korea, Russian Federation, Singapore, South Africa, Spain, Switzerland, Tajikistan, Turkmenistan, and Ukraine Pending: Brazil, Japan (divisional), Singapore (divisional), US (divisional) Methods of Use (In combination with anti - IL - 6/IL - 6R antibodies) 2011 Pending 2032 US Formulations and dosing regimen 2016 Pending 2037 US, Australia, Canada, China, Europe, Israel, Japan Methods of Use (CNS disorders) 2017 Pending 2038 PCT Methods of Use (gastrointestinal/autoimmune/inflammatory) 2018 Pending 2039 Provisional Composition of matter, methods of use, process of manufacturing 2003 Issued/ P e n d i ng 2024 US, Europe, Eurasia, Africa, Algeria, Antigua & Barbuda, Argentina, Australia, Barbados, Bosnia & Herzegovina, Brazil, Canada, Colombia, Costa Rica, Croatia, Cuba, Ecuador, Egypt, Georgia, Iceland, India, Indonesia, Israel, Japan, Korea, Kosovo, Malaysia, Mexico, Mongolia, Montenegro, New Zealand, Nicaragua, Norway, Pakistan, Philippines, Serbia, Singapore, South Africa, Sri Lanka, Taiwan, Thailand, Trinidad & Tobago, Tunisia, Ukraine, Uzbekistan, Venezuela, Vietnam Pending: Several in US and other countries Methods of use (multiple indications) 2008; 2009 Issued 2029; 2030 US, EU, China, Hong Kong, Japan Methods of use (combination therapies with cytotoxics) 2008; 2009 Issued 2029; 2030 US, EU, China, Hong Kong, Japan Compositions of related entities, formulations and methods of treatment 2009 Issued 2030 US, EU, China, Hong Kong, Japan Methods of use (combination therapies with therapeutic antibodies) 2006 Issued 2027 US, EU, China, Japan Formulations of Milciclib and therapeutic combinations of the same for use in the treatment of cancer 2017 Pending 2038 US, PCT Anti IL - 6/IL - 6R A nti b ody T Z L S - 5 0 1 Composition of Matter and Methods of use 2009 Issued/ P e n d i ng 2029 US, Austria, Australia, Belgium, Canada, China, Denmark, France, Germany, Ireland, Italy, Japan Luxembourg, Mexico, Netherland, Spain, Sweden, Switzerland and UK . Pending: US (divisional), Japan (divisional), India 27



C A T A L Y S T S GROWTH OBJECTIVES PRODUCT ACTION/OBJECTIVE DATE Report Phase 1 Nasal Dosing in Healthy Volunteers (Safety, Tolerability and Biomarkers of Immunomodulation) August 2019 Initiate Phase 1 Oral Dosing of Foralumab in Healthy Volunteers 2H 2019 Report Top Line Safety, Efficacy and Exploratory End Point Data from Phase 2a Monotherapy Trial 2H 2019 Initiate Phase 2b Liver Cancer Study of Milciclib in Combination with a TKI 2H 2019 Report Phase 1 Oral Dosing of Foralumab in Healthy Volunteers (Safety, Tolerability and Biomarkers of Anti - inflammation) 1H 2020 Initiate Phase 2 in Crohn’s disease and NASH with Oral Foralumab 2H 2020 28



F I N A N C I N G OBJECTIVES PLANNED USE OF PROCEEDS OBJECTVE CAPITAL ALLOCATION Milciclib Program Advance the Clinical Development – Commence Phase 2b Clinical Trial ~$4.0 Million Foralumab Program Complete Phase 1 Oral Administration Clinical Trial - Healthy Volunteers Commence Phase 2 Nasal Administration Clinical Trial - MS Patients ~$3.0 Million $1.o Million $2.0 Million Other R&D Programs, Working Capital ~$3.0 Million T O T A L ~$10.0 Million CAPITAL STRUCTURE ADS EQUIVALENT* Ordinary Issued Shares Warrants (WAEP : £11.60) Options (WAEP : £16.51) 1 3 , 6 4 6 , 3 8 2 3 6 1 , 7 9 0 1,713,740 Fully Diluted Shares 15,721,912 *Information prepared a of July 24, 2019 1 ADS represents 10 ordinary shares 29



An Innovative Platform in Oral and Nasal Antibody Administration A Novel Approach for Treatment of Hepatocellular Carcinoma CONTACT US US Headquarters Tiziana Life Sciences Inc 420 Lexington Avenue Suite 2525 New York, NY 10170 Research and Development Center Tiziana Life Sciences Inc Pennsylvania Biotechnology Center of Bucks County 3805 Old Easton RD Doylestown, PA 18902 - 8400 UK Headquarters Tiziana Life Sciences plc 55 Park Lane London W 1 K 1 NA United Kingdom + 1 (917) 509 7491 i n f o @ t i z i a n a l i f e s c i e n c e s . c o m T L S A : T I L S :